Most people who search for the “best metabolic health supplement” have already assumed that a product is the answer. The more useful first question is whether supplementation is relevant to their biology at all.
The interest makes sense. A JAMA analysis of NHANES data (2013–2023) found that 38.7% of US adults have metabolic syndrome, and a widely cited 2022 study estimated that only 6.8% of Americans have optimal metabolic health. Many people sense that something has changed, and they want a fix.
Biomarkers determine whether a supplement has anything to work with. These include fasting insulin, HOMA-IR, HbA1c, hs-CRP, and the lipid panel. Marketing copy and ingredient lists cannot answer that question. This article covers what those labs show, how common ingredients compare with the real evidence, and why a lab-based starting point is more credible than a purchase.
Why the Metabolic Health Supplement Market Is Booming Right Now
The category is growing quickly:
- The berberine and metabolic-health supplement market was valued at roughly $295M in 2025 and is projected to reach $320M in 2026, with 8.5% annual growth expected through 2035.
- Weight-management supplements are growing faster still, from $6.69B (2025) to $7.88B (2026), a 17.9% annual growth rate driven largely by “GLP-1 companion nutrition” marketing.
In 2026, product positioning has also shifted toward “gut-first” formulas (prebiotics, probiotics, Akkermansia muciniphila) and botanicals described as GLP-1-pathway-adjacent. This reflects brands responding to competition from GLP-1 medications, not new clinical evidence. More products and more demand do not mean any particular person needs them.
The Problem With Shopping for a Supplement Before Knowing the Numbers
“Metabolic health” is not a single condition. It includes insulin resistance, dyslipidemia, inflammation, and glucose dysregulation. Each has different drivers, and supplements matter differently for each one.
If a supplement targets a biomarker that is already normal, it offers little benefit, no matter how strong the evidence is in other populations. Berberine illustrates this well: its meaningful effects on HbA1c, fasting glucose, and HOMA-IR appear mainly in people who already have dysglycemia, not in those with normal metabolic markers.
The thesis is simple: labs decide relevance before ingredients decide results.
The Labs That Actually Tell You Something
The practical alternative to guessing is a short panel of biomarkers that together describe a person’s real metabolic picture. Clinical cardiometabolic panels, such as Quest Diagnostics’ Cardiometabolic Disease Assessment Panel, combine several tests:
- HbA1c
- An insulin-resistance score
- A lipid panel and ApoB
- TSH
- A comprehensive metabolic panel with FIB-4 index
Together, these provide a far more diagnostic starting point than any single ingredient.
Fasting Insulin and HOMA-IR: Catching Insulin Resistance Early
HOMA-IR is a calculated estimate of insulin resistance based on fasting insulin and fasting glucose. Some lab-testing services note that elevated fasting insulin can appear 5 to 10 years before HbA1c changes become detectable. That makes it one of the earliest signals a person can act on. Someone with normal fasting insulin has little biological reason to take an insulin-sensitizing ingredient like berberine.
HbA1c: The Longer-Term Glucose Picture
HbA1c reflects average blood sugar over roughly three months. It can reveal prediabetes or diabetes trends that a single fasting glucose reading may miss. It was also the primary marker in the berberine trials that showed benefit, and that benefit appeared mainly in people with existing dysglycemia. When HbA1c is consistently normal, blood-sugar-support claims have little relevant biology to act on.
hs-CRP: The Inflammation Signal Most Supplement Marketing Ignores
High-sensitivity C-reactive protein measures low-grade systemic inflammation, which is linked to cardiometabolic risk. Inflammation is central to metabolic syndrome, yet most “metabolic support stack” marketing never mentions inflammation markers. That gap is a useful clue. It helps separate products built around a lab-informed mechanism from products built around a trend.
The Lipid Panel: Where Cardiometabolic Risk Becomes Visible
A standard lipid panel measures LDL, HDL, and triglycerides. ApoB adds a more precise measure of cardiovascular risk. High triglycerides combined with low HDL often signal insulin resistance before glucose markers change. This is why a full panel matters more than any single number. No ingredient should be chosen to “fix” a lipid pattern until testing confirms the pattern exists.
Grading the Evidence: What Metabolic Health Supplements Can and Can’t Do
A tiered framework is more honest than a flat “top 10” list. Ingredients fall into three groups:
- Well supported in specific populations
- Context-dependent
- Weak or unsubstantiated
The tier also depends on who is taking the ingredient. The same compound can help one biomarker profile and do nothing for another.
Berberine: Real Evidence, But Only for Specific Labs
A JAMA Network Open trial found that berberine ursodeoxycholate meaningfully reduced HbA1c in people with type 2 diabetes, with dose-dependent improvements in insulin resistance. A separate JAMA Network Open trial in diabetes-free individuals with obesity and MASLD found no significant effect on visceral fat, liver fat, HbA1c, or insulin resistance markers. Berberine’s evidence applies to people who already have elevated HbA1c or HOMA-IR. It does not support use as a general metabolic boost for people with normal labs.
Chromium, Niacin, Green Tea Extract, Bitter Melon, and Milk Thistle: Commonly Marketed, Weakly Supported
Dietitians caution that these ingredients lack strong evidence for managing metabolic syndrome. Some also carry real safety concerns. Chromium, for example, may interact with insulin and other antidiabetic medications, which matters for anyone already on glucose-lowering treatment. Being popular or widely stocked does not replace trial evidence in the right population.
Broad “Metabolic Support Stacks”: Where the Evidence Breaks Down Most
A controlled 24-week trial tested ten popular ingredients together, including resveratrol, curcumin, green, black, and white tea extracts, quercetin, and fish oil. In non-obese, relatively healthy adults, the combination had no effect on arterial stiffness, endothelial function, or metabolic and cardiovascular markers.
Combining several weakly supported ingredients does not create strong evidence. It adds uncertainty rather than effectiveness. This matches the FTC’s enforcement standard: no dietary supplement has been shown to cause clinically meaningful weight loss without calorie restriction and increased physical activity.
“GLP-1 Companion” Supplements: Marketing Riding a Drug Category, Not New Clinical Data
This category has grown by rebranding around the popularity of GLP-1 medications. There is no evidence that any botanical mimics GLP-1 pathways in a clinically meaningful way.
Regulators are paying attention. In June 2026, the FTC sued Amare Global Holdings over unsubstantiated health claims and then filed a contempt motion. A class action was also filed against Veracity Wellness, alleging it marketed a supplement by comparing it to a branded GLP-1 medication for appetite suppression and weight loss. Products described as “GLP-1 support” or “GLP-1 alternatives” deserve the same skepticism as any unsubstantiated metabolic claim. Labs, not labels, show what is actually happening in the body.
What About Continuous Glucose Monitors? A Related but Different Tool
Over-the-counter continuous glucose monitors (CGMs) have been FDA-cleared for adults without diabetes since 2024. They are part of the same “metabolic wellness” trend driving supplement interest. Physicians raise several cautions:
- There are no established guidelines for interpreting CGM data in healthy users.
- Long-term outcome evidence is limited.
- Over-monitoring normal glucose swings can cause health anxiety.
CGMs work best as a behavioral feedback tool. They are not a diagnostic shortcut and do not replace a proper lab panel.
Why Lab-Based Assessment, Not a Purchase, Is the Credible Starting Point
The value of a supplement depends on a person’s biomarker status, and most marketing skips that step. The FTC action against Amare Global, along with the Veracity Wellness class action, shows that unsubstantiated metabolic claims are a current legal and consumer-protection issue.
A clinical assessment of fasting insulin, HOMA-IR, HbA1c, hs-CRP, the lipid panel, and related markers shows what is happening before any product decision. It also clarifies whether the situation calls for a supplement, a medication, or a lifestyle change.
Red Mountain’s Foundation stage follows this model. Metabolic assessment and initial labs come first. The tools are chosen afterward to match what the labs show. These may include nutrition strategy, hormone evaluation, targeted supplementation, or medical weight-loss support. Medical support can include GLP-1 medications used under clinical supervision, with compounded options among them. Medication is one tool, while structure and ongoing clinical guidance carry the plan. That approach reflects more than 30 years of patient care.
Conclusion: Let Your Labs Decide Before a Product Does
For most people, “best metabolic health supplement” is the wrong question until they know their own numbers. The evidence breaks down this way:
- Berberine helps a specific group of people with existing dysglycemia.
- Broad stacks and several commonly marketed ingredients show little benefit in generally healthy adults.
- GLP-1-adjacent marketing claims deserve particular skepticism.
Sustainable metabolic health comes from matching the right tool to a documented biomarker picture, not choosing a product first and hoping the biology fits.
Next Step: Start With a Clinical Metabolic Assessment
Before considering any metabolic health supplement, a person benefits from a clear read on fasting insulin, HOMA-IR, HbA1c, hs-CRP, and the lipid panel. This is the kind of assessment Red Mountain walks patients through in a consult. Clinicians review the labs, explain what they mean, and turn them into a personalized plan. For anyone whose body seems to have changed despite doing everything right, a consult is usually the next step toward clarity.
Red Mountain may prescribe a compounded version of a GLP-1. Compounded GLP-1s contain semaglutide or tirzepatide. Compounded GLP-1s have not been approved by the FDA or reviewed by the FDA for safety, effectiveness, or quality. Compounded GLP-1s have not been demonstrated to the FDA to be safe or effective for weight loss. Compounded GLP-1s manufacturing processes have not been reviewed by the FDA. FDA-approved products containing semaglutide and tirzepatide are available. Ask your provider for more information.
